is glp-1 patented Patent Landscape: Who Leads the Innovation Race Pharma or Food? Lemme Reset™ GLP-1 Production Support
Description
Incretin-based therapies in obesity-related kidney disease In recent years, studies have been expanded to investigate the effects of incretin-based therapies on kidney outcomes in overweight/obese individuals without T2D

Available online at: (accessed March 21, 2022)
Diabetes-specific formula with standard of care improves glycemic control, body composition, and cardiometabolic risk factors in overweight and obese adults with type 2 diabetes: results from a randomized controlled trial
Does GIPR agonism improve GLP-1RA tolerance

If approved, a treatment plan and prescription are issued by the prescribing clinician